Exscientia plc(EXAI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EXAI Exscientia plc

Halted 11-19 16:00:00 EST

4.84

+0.00

0.00%

High4.84	Low4.84	Vol0.00
Open4.84	D1 Closing4.84	Amplitude0.00%
Mkt Cap633.50M	Tradable Cap407.94M	Total Shares130.89M
T/O7.15M	T/O Rate0.00%	Tradable Shares84.29M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"EXAI","market":"US","secType":"STK","nameCN":"Exscientia plc","latestPrice":4.84,"timestamp":1732050000000,"preClose":4.84,"halted":3,"volume":0,"delay":0,"floatShares":84285540,"shares":130888168,"eps":-1.591469,"marketStatus":"Halted","change":0,"latestTime":"11-19 16:00:00 EST","open":4.84,"high":4.84,"low":4.84,"amount":7149550.4901903,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.591469,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1736499600000},"marketStatusCode":7,"adr":0,"adrRate":1,"listingDate":1633060800000,"exchange":"NASDAQ","adjPreClose":4.84,"volumeRatio":0},"requestUrl":"/m/hq/s/EXAI","defaultTab":"news","newsList":[{"id":"2495715795","title":"Expertai Acquires Business Unit From Finix Technology Solutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2495715795","media":"T-Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495715795?lang=en_us&edition=fundamental","pubTime":"2024-12-31 01:29","pubTimestamp":1735579748,"startTime":"0","endTime":"0","summary":"ExpertAi SpA :Acquires Business Unit From Finix Technology Solutions.Consideration Of Eur 0.7 Million, Possible Earn-Out Of Up To Eur 0.5 Million.Signs With Finix Technology Solutions Commercial Agree","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.trkd.thomsonreuters.com","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXAI","BK4139"],"gpt_icon":0},{"id":"2488972220","title":"Recursion Pharmaceuticals CFO Ben Taylor to Join Exscientia","url":"https://stock-news.laohu8.com/highlight/detail?id=2488972220","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488972220?lang=en_us&edition=fundamental","pubTime":"2024-12-04 06:02","pubTimestamp":1733263320,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals ( ($RXRX) ) has shared an update. Ben Taylor, CFO of Recursion Pharmaceuticals, is set to join Exscientia AI Ltd. with a ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/recursion-pharmaceuticals-cfo-ben-taylor-to-join-exscientia?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/recursion-pharmaceuticals-cfo-ben-taylor-to-join-exscientia?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EXAI","BK4539","BK4548","BK4139","RXRX"],"gpt_icon":0},{"id":"2488439549","title":"Recursion Pharmaceuticals (RXRX) Bold Acquisition Places it as an Industry Leader","url":"https://stock-news.laohu8.com/highlight/detail?id=2488439549","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488439549?lang=en_us&edition=fundamental","pubTime":"2024-12-03 22:11","pubTimestamp":1733235072,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals ($)RXRX, a trailblazer in AI-powered drug discovery, recently acquired its competitor, Exscientia, in a strategic move th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/recursion-pharmaceuticals-rxrx-bold-acquisition-makes-it-a-leader-in-ai-drug-discovery?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/recursion-pharmaceuticals-rxrx-bold-acquisition-makes-it-a-leader-in-ai-drug-discovery?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","EXAI","BK4548","RXRX"],"gpt_icon":0},{"id":"2485634344","title":"Hold Rating Recommended for Recursion Pharmaceuticals Post-Merger with Exscientia: Upside Potential Amidst Clinical Uncertainties","url":"https://stock-news.laohu8.com/highlight/detail?id=2485634344","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485634344?lang=en_us&edition=fundamental","pubTime":"2024-11-21 18:28","pubTimestamp":1732184899,"startTime":"0","endTime":"0","summary":"Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Recursion Pharmaceuticals (RXRX – Research Report), reducing the p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/hold-rating-recommended-for-recursion-pharmaceuticals-post-merger-with-exscientia-upside-potential-amidst-clinical-uncertainties?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/hold-rating-recommended-for-recursion-pharmaceuticals-post-merger-with-exscientia-upside-potential-amidst-clinical-uncertainties?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EXAI","RXRX","POST"],"gpt_icon":0},{"id":"2484110738","title":"Exscientia and Recursion Merge to Revolutionize Drug Discovery","url":"https://stock-news.laohu8.com/highlight/detail?id=2484110738","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484110738?lang=en_us&edition=fundamental","pubTime":"2024-11-20 22:49","pubTimestamp":1732114189,"startTime":"0","endTime":"0","summary":"Exscientia Plc (EXAI) has released an update. Exscientia Plc merges with Recursion to form a powerful AI-driven drug discovery platform, marking a ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/exscientia-and-recursion-merge-to-revolutionize-drug-discovery?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/exscientia-and-recursion-merge-to-revolutionize-drug-discovery?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EXAI"],"gpt_icon":0},{"id":"2484111366","title":"Recursion Pharmaceuticals, Exscientia Complete Business Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2484111366","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484111366?lang=en_us&edition=fundamental","pubTime":"2024-11-20 21:50","pubTimestamp":1732110635,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals (RXRX) said Wednesday that it has completed its business combination with Exscientia (EXAI) and Exscientia is now a wholly owned unit of Recursion.Exscientia's American depos","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","EXAI","RXRX","BK4539","BK4548"],"gpt_icon":1},{"id":"2484192099","title":"Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery","url":"https://stock-news.laohu8.com/highlight/detail?id=2484192099","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484192099?lang=en_us&edition=fundamental","pubTime":"2024-11-20 20:00","pubTimestamp":1732104000,"startTime":"0","endTime":"0","summary":"Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs. Platform will focus on first and best-in-class drug discovery and development, demonstrating the ability to find novel insights and dramatically reduce the time and cost of discovery. “I believe the combination of the incredible teams and platforms at Exscientia and Recursion position us as the leader of the AI-enabled drug discovery and development space,” said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion. “With more than 10 clinical and preclinical programs in the internal pipeline, more than 10 partnered programs and over $450M in upfront and realized milestone payments received from partners to date out of more than $20B possible, we are advancing a flywheel of discovery and creating value in our pipeline through technology.”","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/EKlb2kf5KjRU9MYGIM7Lhw--~B/aD0yMDQ4O3c9NDE3NTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/033b1e25fec316dbc53b50cd356ec175","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/EKlb2kf5KjRU9MYGIM7Lhw--~B/aD0yMDQ4O3c9NDE3NTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/033b1e25fec316dbc53b50cd356ec175"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/recursion-exscientia-two-leaders-ai-120000019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","EXAI","BK4139","OS","RXRX"],"gpt_icon":1},{"id":"2483347265","title":"Barclays Sticks to Its Hold Rating for Exscientia Plc (EXAI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483347265","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483347265?lang=en_us&edition=fundamental","pubTime":"2024-11-15 17:56","pubTimestamp":1731664572,"startTime":"0","endTime":"0","summary":"In a report released today, Peter Lawson from Barclays maintained a Hold rating on Exscientia Plc (EXAI – Research Report), with a price target of ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-its-hold-rating-for-exscientia-plc-exai?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-its-hold-rating-for-exscientia-plc-exai?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EXAI"],"gpt_icon":0},{"id":"2483832056","title":"Expert.ai Strengthens Governance with Leadership Change","url":"https://stock-news.laohu8.com/highlight/detail?id=2483832056","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483832056?lang=en_us&edition=fundamental","pubTime":"2024-11-14 01:22","pubTimestamp":1731518526,"startTime":"0","endTime":"0","summary":"Expert.ai S.p.A. (IT:EXAI) has released an update. Expert.ai S.p.A. has appointed Ambrosella Landonio as a new member of the Management Control Com...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/expert-ai-strengthens-governance-with-leadership-change?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/expert-ai-strengthens-governance-with-leadership-change?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EXAI"],"gpt_icon":0},{"id":"2483106833","title":"Recursion and Exscientia Merger Approved by Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2483106833","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483106833?lang=en_us&edition=fundamental","pubTime":"2024-11-13 23:59","pubTimestamp":1731513583,"startTime":"0","endTime":"0","summary":"Exscientia Plc (EXAI) has released an update. Shareholders of Recursion and Exscientia have overwhelmingly approved a merger, expected to be finali...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/recursion-and-exscientia-merger-approved-by-shareholders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/recursion-and-exscientia-merger-approved-by-shareholders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EXAI"],"gpt_icon":0},{"id":"2483830172","title":"Recursion Pharmaceuticals, Exscientia Shareholders Approve Proposed Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2483830172","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483830172?lang=en_us&edition=fundamental","pubTime":"2024-11-13 22:47","pubTimestamp":1731509268,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals  and Exscientia  said Wednesday that their respective shareholders have approved their proposed combination.The deal is expected to be completed Nov. 20, the companies said.Shares of Recursion rose 1.9% and Exscientia climbed 2% in recent trading.Price: 7.77, Change: +0.19, Percent Change: +2.51","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4548","RXRX","BK4539","BK4139","EXAI"],"gpt_icon":0},{"id":"2483886265","title":"Recursion, Exscientia shareholders approve proposed combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2483886265","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483886265?lang=en_us&edition=fundamental","pubTime":"2024-11-13 22:16","pubTimestamp":1731507371,"startTime":"0","endTime":"0","summary":"Recursion (RXRX) and Exscientia plc (EXAI) have each received overwhelming approval from their shareholders for the proposed combination between Re...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/recursion-exscientia-shareholders-approve-proposed-combination?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/recursion-exscientia-shareholders-approve-proposed-combination?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","EXAI","BK4539","RXRX","BK4139"],"gpt_icon":0},{"id":"2483470885","title":"BRIEF-Recursion And Exscientia Shareholders Approve The Proposed Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2483470885","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483470885?lang=en_us&edition=fundamental","pubTime":"2024-11-13 22:09","pubTimestamp":1731506943,"startTime":"0","endTime":"0","summary":"Nov 13 (Reuters) - Recursion Pharmaceuticals Inc :   * RECURSION AND EXSCIENTIA SHAREHOLDERS APPROVE THE PROPOSED COMBINATIONSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXAI","BK4539","RXRX","BK4139","BK4548"],"gpt_icon":0},{"id":"2483885765","title":"Press Release: Recursion and Exscientia Shareholders Approve the Proposed Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2483885765","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483885765?lang=en_us&edition=fundamental","pubTime":"2024-11-13 22:08","pubTimestamp":1731506880,"startTime":"0","endTime":"0","summary":"Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close. Salt Lake City USA, Oxford UK, Nov. 13, 2024  -- Recursion  and Exscientia plc  have each received overwhelming approval from their shareholders for the proposed combination between Recursion and Exscientia.The transaction is expected to close on November 20, 2024, subject to the satisfaction or waiver of the remaining customary closing conditions. Recursion expects to host an update call after the anticipated close on November 20, 2024 at 7:30 a.m. ET /  5:30 a.m MT / 12:30 p.m. GMT. The company will broadcast the live stream from Recursion's X , LinkedIn and YouTube accounts. Questions can be submitted via this link ahead of time or during the livestream.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXAI","BK4139","OS","BK4548","BK4097","BK4539","RXRX"],"gpt_icon":0},{"id":"2483488077","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2483488077","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483488077?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:00","pubTimestamp":1731495600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DGII","KMDA","ADAP","CINT","BZH","ICAD","UGP","CREX","CPRT","GOEV","SHCO","MIST","DFLI","BRAG","CELC","MURA","KORE","HI","SLE","LQDA","CIG","BN","DTI","SONO","MCRB","DMAC","LVLU","GAMB","BOXL","IVVD","AFCG","DNMR","EXAI","GLOB","ASND","AMAT","SLRN","INO","BRFS","ENLT","HBM","HAYN","JD","EC","BEEM","INKT","BLRX","INVZ","KRMD"],"gpt_icon":1},{"id":"2481602454","title":"Exscientia PLC  expected to post a loss of 9 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2481602454","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481602454?lang=en_us&edition=fundamental","pubTime":"2024-11-06 22:01","pubTimestamp":1730901682,"startTime":"0","endTime":"0","summary":"Exscientia PLC  expected to post a loss of9cents a share - Earnings Preview Exscientia PLC EXAI.OQ EXAI.O is expected to show a rise in quarterly revenue when it reports  results on November 7 (estima","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nL8N3MD2QN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXAI"],"gpt_icon":0},{"id":"2481672859","title":"Exscientia Plc Enhances Board Collaboration with Recursion","url":"https://stock-news.laohu8.com/highlight/detail?id=2481672859","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481672859?lang=en_us&edition=fundamental","pubTime":"2024-11-06 19:31","pubTimestamp":1730892703,"startTime":"0","endTime":"0","summary":"Exscientia Plc (EXAI) has released an update. Exscientia Plc has announced a key amendment to its transaction agreement with Recursion Pharmaceutic...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/exscientia-plc-enhances-board-collaboration-with-recursion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/exscientia-plc-enhances-board-collaboration-with-recursion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EXAI"],"gpt_icon":0},{"id":"2479014102","title":"Press Release: Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th","url":"https://stock-news.laohu8.com/highlight/detail?id=2479014102","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479014102?lang=en_us&edition=fundamental","pubTime":"2024-10-30 20:22","pubTimestamp":1730290920,"startTime":"0","endTime":"0","summary":"Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia. Salt Lake City, UT, Oct. 30, 2024  -- Recursion , a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its Q3 2024 financial results on Wednesday, Nov 6, 2024, following the close of the financial markets.The company will not host its normal L Call in relation to the business updates and financials for the third quarter. Instead, the company expects to host an update call after the anticipated close of the proposed business combination with Exscientia, which is expected to be on Nov 20, 2024. We will broadcast the live stream from Recursion's X , LinkedIn and YouTube accounts and there will be opportunities to ask questions of the company.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","EXAI","RXRX","BK4548"],"gpt_icon":1},{"id":"2475964129","title":"Exscientia to receive $15M in milestones for Sanofi collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2475964129","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475964129?lang=en_us&edition=fundamental","pubTime":"2024-10-16 20:39","pubTimestamp":1729082346,"startTime":"0","endTime":"0","summary":"Exscientia plc  announced the advancement of two additional discovery programmes within its collaboration with Sanofi, with Exscientia receiving an aggregate of $15M in milestone payments. Both lead compounds have met the product profile requirements, set by both Exscientia and Sanofi, to enable a transition to the lead optimisation phase within the collaboration.  The payment is expected to be received by Exscientia in the fourth quarter of 2024 and reflected as cash inflows from collaborations and recognised as revenue over the duration of the collaboration. For these two programs, Exscientia may receive over $300M in pre-commercial and over $300M in commercial milestone payments, plus tiered royalties on sales ranging from high single digits to mid-teens, contingent on achieving specific research, development, regulatory, and commercial milestones. Source: Press Release","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4164408-exscientia-to-receive-15m-in-milestones-for-sanofi-collaboration","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["EXAI","BK4139"],"gpt_icon":0},{"id":"2475954964","title":"Exscientia Expects $15 Million in Milestone Payments From Sanofi","url":"https://stock-news.laohu8.com/highlight/detail?id=2475954964","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475954964?lang=en_us&edition=fundamental","pubTime":"2024-10-16 19:39","pubTimestamp":1729078779,"startTime":"0","endTime":"0","summary":"Exscientia  said Wednesday it expects to receive in Q4 a total of $15 million in milestone payments after advancing two drug programs in its collaboration with Sanofi .Exscientia said both compounds met the requirements set by both companies to enable a transition to an optimization phase in the collaboration.The drug development company said it remains eligible to receive additional pre-commercial milestone payments of over $300 million and commercial milestones of over $300 million as well as tiered royalties as part of the Sanofi collaboration.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EXAI","IE00BFXG1179.USD","BK4588","SNYNF","BK4585","SNY","BK4007","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.exscientia.ai","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0.0276},{"period":"6month","weight":-0.1494},{"period":"1year","weight":-0.2194},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0251},{"period":"3month","weight":0.0232},{"period":"6month","weight":0.0527},{"period":"1year","weight":0.244},{"period":"ytd","weight":0.0058}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité  Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.045404},{"month":2,"riseRate":0.333333,"avgChangeRate":0.003726},{"month":3,"riseRate":0,"avgChangeRate":-0.158386},{"month":4,"riseRate":0,"avgChangeRate":-0.139823},{"month":5,"riseRate":1,"avgChangeRate":0.222499},{"month":6,"riseRate":0,"avgChangeRate":-0.114889},{"month":7,"riseRate":0.666667,"avgChangeRate":0.144398},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.092223},{"month":9,"riseRate":0,"avgChangeRate":-0.174444},{"month":10,"riseRate":0.333333,"avgChangeRate":0.01684},{"month":11,"riseRate":0.25,"avgChangeRate":-0.021174},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.03589}],"exchange":"NASDAQ","name":"Exscientia plc","nameEN":"Exscientia plc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Exscientia plc(EXAI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Exscientia plc(EXAI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Exscientia plc,EXAI,Exscientia plc股票,Exscientia plc股票老虎,Exscientia plc股票老虎国际,Exscientia plc行情,Exscientia plc股票行情,Exscientia plc股价,Exscientia plc股市,Exscientia plc股票价格,Exscientia plc股票交易,Exscientia plc股票购买,Exscientia plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Exscientia plc(EXAI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Exscientia plc(EXAI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction